Michel Forni

TL;DR: This article reviews data on one aspect of the magic bullet concept, the use of radiolabelled antibodies as tracers for tumour localization, and discusses the very recent clinical use of (131)I-labelled Mabs against carcinoembryonic antigen.

TL;DR: Purified, [131I]-labeled goat antibodies against carcinoembryonic antigen, which have been shown to localize in human carcinoma in nude mice, were injected into patients with carcinoma and demonstrated that only the anti-CEA antibodies localized in tumors.

TL;DR: CERN-MEDICIS is a facility dedicated to research and development in life science and medical applications as discussed by the authors, which was inaugurated in October 2014 and will produce an increasing range of innovative isotopes using the proton beam of ISOLDE for fundamental studies in cancer research, for new imaging and therapy protocols in cell and animal models and for preclinical trials, possibly extended to specific early phase clinical studies (phase 0) up to phase I trials.

TL;DR: The preliminary data indicate that bazedoxifene is a potential new therapeutic option for pancreatic and gastric cancer therapy, safe to use and at low cost and it might be administrated at an early stage with current strategies.

TL;DR: Research on tumor localization by radiolabeled antibodies was initiated almost 30 years ago by Pressman and Korngold (1953), who showed that labeled antibodies against Wagner osteosarcoma were concentrated in vivo in these tumors.